Ipca Laboratories Ltd.
NSE: IPCALAB · Pharmaceuticals
Snapshot
Unlock Ipca Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ipca Laboratories Limited is an integrated pharmaceutical company engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished pharmaceutical formulations. The company operates across a broad spectrum of therapeutic segments, including cardiology, rheumatology, and anti-malarial treatments, serving both domestic and international markets.
Business Model
The company generates revenue through the production and sale of a diverse portfolio of generic and branded formulations alongside high-quality APIs. It leverages a global distribution network, exporting products to approximately 100 countries to sustain its market presence.
Growth Outlook
Growth is driven by the expansion of its extensive therapeutic portfolio and the strengthening of its global export footprint. The company continues to focus on maintaining its leadership in key segments like anti-malarials and anti-hypertensives.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality standards and inspections by international health authorities such as the USFDA.
- Currency Volatility. As a major exporter to over 100 countries, the company is exposed to fluctuations in foreign exchange rates which can impact profit margins.
- Input Cost Inflation. Volatility in the prices of raw materials and key starting materials for APIs can adversely affect the cost of production.
- Geopolitical Instability. Operations and exports in diverse international markets are subject to geopolitical tensions and changing trade policies.
Start your research today
Unlock AI insights, financials, peers and live data on Ipca Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹10,126 Cr
TTM · consolidated
NET PROFIT
₹1,375 Cr
TTM · consolidated
EPS
₹51.63
TTM · consolidated
RETURN ON EQUITY
18.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
19.4%
TTM · consolidated
P/E
38.1x
Q1 FY27 · consolidated
EV/EBITDA
20.9x
Q1 FY27 · consolidated
EBITDA MARGIN
23.7%
TTM · consolidated
NET PROFIT MARGIN
15.2%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Ipca Laboratories Ltd.IPCALAB | ₹49,860 Cr | 38.07 | 20.90 | 10.6% | 23.7% | 18.3% | 19.4% | +46.8% |
Alkem Laboratories Ltd.ALKEM | ₹62,054 Cr | 28.76 | 17.47 | 13.4% | 24.1% | 17.1% | 20.5% | -2.1% |
Abbott India Ltd.ABBOTINDIA | ₹55,386 Cr | 35.69 | 25.20 | 8.1% | 31.5% | 35.5% | 45.4% | -19.0% |
Glaxosmithkline Pharmaceuticals Ltd.GLAXO | ₹50,112 Cr | 47.70 | 32.70 | 5.8% | 37.9% | 50.6% | 61.2% | +3.7% |
Gland Pharma Ltd.GLAND | ₹48,373 Cr | 42.80 | 21.85 | 17.6% | 30.8% | 11.6% | 15.7% | +55.5% |
Ajanta Pharmaceuticals Ltd.AJANTPHARM | ₹43,288 Cr | 38.14 | 25.77 | 20.2% | 29.1% | 27.3% | 34.4% | +33.2% |
As of Q1 FY27
Financials
Ipca Laboratories Ltd.
NSE: IPCALAB · Pharmaceuticals
Snapshot
Unlock Ipca Laboratories Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Ipca Laboratories Limited is an integrated pharmaceutical company engaged in the manufacturing and marketing of active pharmaceutical ingredients (APIs) and finished pharmaceutical formulations. The company operates across a broad spectrum of therapeutic segments, including cardiology, rheumatology, and anti-malarial treatments, serving both domestic and international markets.
Business Model
The company generates revenue through the production and sale of a diverse portfolio of generic and branded formulations alongside high-quality APIs. It leverages a global distribution network, exporting products to approximately 100 countries to sustain its market presence.
Growth Outlook
Growth is driven by the expansion of its extensive therapeutic portfolio and the strengthening of its global export footprint. The company continues to focus on maintaining its leadership in key segments like anti-malarials and anti-hypertensives.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality standards and inspections by international health authorities such as the USFDA.
- Currency Volatility. As a major exporter to over 100 countries, the company is exposed to fluctuations in foreign exchange rates which can impact profit margins.
- Input Cost Inflation. Volatility in the prices of raw materials and key starting materials for APIs can adversely affect the cost of production.
- Geopolitical Instability. Operations and exports in diverse international markets are subject to geopolitical tensions and changing trade policies.
Start your research today
Unlock AI insights, financials, peers and live data on Ipca Laboratories Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹10,126 Cr
TTM · consolidated
NET PROFIT
₹1,375 Cr
TTM · consolidated
EPS
₹51.63
TTM · consolidated
RETURN ON EQUITY
18.3%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
19.4%
TTM · consolidated
P/E
38.1x
Q1 FY27 · consolidated
EV/EBITDA
20.9x
Q1 FY27 · consolidated
EBITDA MARGIN
23.7%
TTM · consolidated
NET PROFIT MARGIN
15.2%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27